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BACKGROUND: Activator protein-2a (AP-2a) is a transcription factor that belongs to the family of AP-2 proteins that have essential
roles in tumorigenesis. Indeed, AP-2a is considered as a tumour-suppressor gene in different tissues such as colonic, prostatic or
breast epithelial cells. Moreover, AP-2a also participates in the control of colon and breast cancer cells sensitivity towards
chemotherapeutic drugs. Despite its potential interest, very few data are available regarding the roles of AP-2a in pancreatic cancer.
METHODS: We have developed a stable pancreatic CAPAN-1 cell line overexpressing AP-2a. Consequences of overexpression were
studied in terms of in vivo cell growth, gene expression, migration capacity and chemosensitivity.
RESULTS: In vivo tumour growth of CAPAN-1 cells overexpressing AP-2a was significantly decreased by comparison to control cells.
An altered expression pattern of cell cycle-controlling factors (CDK-4, CDK-6, cyclin-G1, p27
kip1 and p57
kip2) was observed in
AP-2a-overexpressing clones by microarrays and western blot analysis. Promoter activity and ChIP analysis indicated that
AP-2a induces p27
kip1 protein levels by direct binding to and transactivation of its promoter. Moreover, AP-2a overexpression
increased the chemosensitivity of CAPAN-1 cells to low doses of gemcitabine and reduced their in vitro migration capacity.
CONCLUSION: Our data suggested that AP-2a overexpression could be exploited to decrease in vivo tumour growth of pancreatic
cancer cells and to increase their sensitivity to gemcitabine.
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Activator protein-2a (AP-2a) belongs to the AP-2 family of
transcription factors that comprises five members encoded by
separate genes. All AP-2 proteins share two functional domains,
that is, a proline/glutamine-rich transactivation domain and a
helix-turn-helix DNA-binding domain. This last one allows AP-2
proteins to bind to GC-rich consensus regions located in the
promoters of their target genes (Eckert et al, 2005). As recently
reviewed (Orso et al, 2008), AP-2 proteins have relevant roles in
tumorigenesis by regulating some key genes involved in cell
proliferation (ErbB-2, c-myc proto-oncogenes), cell cycle regula-
tion (CDKN1A), cell adhesion and invasion (MMP-2, MMP-9,
PAR-1 and MUC18). Moreover, several lines of evidence suggested
that AP-2a might behave as a tumour-suppressor gene (TSG) in
several tissues. For example, loss of AP-2a expression was reported
in metastatic melanoma cells (Tellez et al, 2003), in prostate (Ruiz
et al, 2001) and colon cancer cells (Schwartz et al, 2007). In breast
cancer cells, contrasting results were reported in the literature.
Earlier studies suggested that AP-2 proteins promote the
malignant potential of breast cancer cells by transactivating the
promoters of ErbB-2 and ErbB-3 (Bosher et al, 1996). However,
recent data using shRNA to knockdown AP-2a expression in breast
cancer cell lines showed that AP-2a inhibits tumour growth both
in vitro and in vivo (Orso et al, 2008). Besides being a potential
TSG, AP-2a also participates in the control of colon and breast
cancer cells sensitivity towards chemotherapeutic drugs
(Wajapeyee et al, 2005). Despite its potential interest, very few
data are available regarding the roles of AP-2a in pancreatic cancer
(Vernimmen et al, 2003). Recently we showed that, in human
pancreas (Fauquette et al, 2007), AP-2a was expressed by almost
66% of non-tumoural ductal cells and endocrine cells by
immunohistochemistry, whereas its expression was decreased to
only 5.5% of pancreatic ductal adenocarcinoma (PDAC). We also
showed that the expression of AP-2a was mutually exclusive with
that of the human epithelial mucin, MUC4, which is a specific
marker of this condition, being expressed in 83% of the PDAC
samples. These data suggested that AP-2a might also behave as a
TSG in human PDAC.
Interestingly, PDAC corresponds to the most frequent histolo-
gical form of pancreatic cancer, which remains a devastating
condition with only 3% of patients alive at 5 years after diagnosis.
This is because of the inability to detect cancer at onset, its
aggressiveness and the lack of effective therapies (Schneider et al,
2005). Indeed, at the time of diagnosis, more than 80% of patients
have locally advanced or incurable metastatic disease. Gemcita-
bine, the only approved drug for the treatment of pancreatic
cancer, offers a partial response in o6% of the patients (Chua and
Cunningham, 2006). Our interest first focused on the epithelial
mucin, MUC4, in this disease because it is not expressed by normal
pancreatic tissue but is gradually expressed during pancreatic Revised 15 June 2009; accepted 17 June 2009
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scarcinogenesis from the premalignant lesions, that is, pancreatic
intraepithelial neoplasia (PanIN) type 1 (which are MUC4-positive
in 17% of the cases) to PDAC (Swartz et al, 2002).
Moreover, experimental data showed that the knockdown of
MUC4 expression by shRNA in HPAF cancer cell line is
accompanied by a significant decrease of cell proliferation
in vitro, tumour growth and incidence of metastasis in vivo
(Chaturvedi et al, 2007), suggesting that MUC4 could have an
important role in pancreatic carcinogenesis. Indeed, MUC4 forms
a protein complex with the ErbB-2 receptor in human pancreatic
cancer cells and modulates its downstream signalling (Chaturvedi
et al, 2008).
To decipher the molecular mechanisms that govern MUC4
expression in pancreatic cancer, we previously characterised its
promoter and identified several consensus binding sites for AP-2
transcription factor (Perrais et al, 2001). In our recent study, we
showed that AP-2a is a trans-repressor factor of MUC4 promoter
in two well-differentiated pancreatic cancer cell lines that
expressed MUC4. We thus produced several stable clones derived
from CAPAN-1 cell line that stably overexpressed AP-2a. These
clones are characterised by a strong downregulation of MUC4
along with a strong upregulation of the cdk inhibitor, p27
kip1
(Fauquette et al, 2007). Interestingly, we also showed that these
clones exhibited a significant decrease of in vitro cell growth and
cell invasion. In this study, our aims were to evaluate whether
AP-2a overexpression could modulate the phenotype of the
parental CAPAN-1 cell line in terms of chemosensitivity, migration
capacity, pattern of gene expression, topography of epithelial
markers expression and in vivo cell growth.
MATERIALS AND METHODS
Total cellular extract preparation and western blotting
After scraping, the cells were pelleted, washed with 1  phosphate-
buffered saline (PBS) and incubated in lysis buffer (50mM Tris–
HCl pH 7.5, containing 150mM NaCl, 1% (w/v) NP40, 5mM sodium
fluoride, 5mM sodium orthovanadate, 0.25% (w/v) sodium
deoxycholate and a cocktail of protease inhibitors) for 30min at
41C. After 10min of centrifugation at 13210g (41C), the super-
natant (total extract) was stored at  801C. Western blots were
carried out as previously described (Fauquette et al, 2005).
Peroxydase-conjugated secondary antibodies were used and
immunoreactive bands were visualised using the West Pico
chemoluminescent substrate (Perbio, Brebie `res, France).
Confocal microscopy
Cells were fixed with 4% paraformaldehyde (w/v) for 20min,
quenched for 20min with 50mM NH4Cl in PBS and permeabilised
with 0.2%. (w/v) saponin in PBS for 20min. The saturation step
was performed for 20min in PBS containing 1% bovine serum
albumin (BSA) and 0.2% saponin (w/v). Cells were then incubated
overnight with different primary antibodies diluted in PBS
containing 1% BSA and 0.2% saponin. After PBS washings, cells
were incubated for 2h with secondary fluorescein isothiocyanate
or tetra methyl rhodamine isothiocyanate (TRITC)-conjugated
antibodies. Laser microscopy analysis was carried out using a
Leica instrument (Model TCS-NT) with a 63 1.32 Plan-Apoc-
hromat oil-immersion objective lens (Leica Microsystems, Cedex,
France). Files of microphotographs were processed with Adobe
Photoshop 5.0. (San Jose, CA, USA).
Antibodies
For confocal microscopy analysis, monoclonal antibodies against
MUC1 (214D4) and MUC4 (m8G7) were used. These were kind
gifts from J Hilkens (The Netherlands Cancer institute, Amster-
dam, The Netherlands) and SK Batra (Eppley Cancer Institute,
Omaha, NE, USA), respectively. For western blotting, membranes
were probed with antibodies against ErbB-2 (NCL CB11 from Novo
Castra, dilution 1/250), cyclin-D1 (sc-718, dilution 1/500), cyclin-
G1 (sc-7865, dilution 1/500), cdk-4 (sc-601, dilution 1/1000), cdk-6
(sc-177, dilution 1/1000), p57 (sc-1040, dilution 1/2000, all from
Santa Cruz Biotechnology Inc., Heidelberg, Germany) or b-actin
(A5441, dilution 1/5000 from Sigma, St Quentin Fallerier, France).
Subcutaneous (s.c.) xenografts
CAPAN-1 cells and its deriving clones were injected s.c. (4 10
6
cells in 0.4ml of RPMI) into athymic female nude mice that were
bred and maintained in pathogen-free conditions (six mice per cell
type). Tumour development was followed periodically. The tumour
volume (mm
3) was determined by the equation V¼W
2.L/2, in
which W corresponds to the width (in mm) and L to the tumour
length (in mm). Mice were killed at days 22 or 28 after inoculation.
All animal procedures were in accordance with the guidelines of
the animal care committee. For each subcutaneous tumour, one
tissue fragment was fixed in formalin before inclusion into
paraffin.
Microarrays
To monitor gene expression in response to AP-2a overexpression,
RNA was prepared from C5, a27 and a42 clones using Macherey
Nagel NucleoSpin RNA II kit (Hoerdt, France). RNA quality was
checked using the Agilent 2100 Bioanalyser (IFR 114 facility,
Agilent Technologies, Massy, France). The complementary labelled
RNA probe was synthesised using the Truelabeling AMP kit
(SuperArray Bioscience, SA Biosciences, TebuBio, Le Perray-
en-Yvelines, France) and biotin-16-UTP (Roche, Meyba, France),
and hydridised with the cell cycle OligoGEArray (SuperArray
Bioscience). Signal was generated using the ECF substrate (GE
Health care, Orsey, France), and detected using the storm system,
and analysed using the GEArray Expression Analysis Suite (Super-
Array Bioscience) with normalisation with housekeeping genes.
Transient transfections
The pancreatic cancer cells, CAPAN-1, were transfected with 0.5mg
of the pGVB2 basic vector carrying promoter elements of p27
kip1
gene (CDKN1B) upstream of the luciferase gene (kind gift from Pr
T Sakai, Kyoto Prefectural University of medicine, Kyoto, Japan) as
previously described (Fischer et al, 2005), and 0.25mgo fa n
expression vector encoding AP-2a (pRSV-AP-2 gift from Dr H
Hurst, ICRF Molecular Oncology Unit, London, UK). Results were
expressed as fold induction relative to the cotransfection
performed in the presence of the corresponding empty expression
vector, as previously described (Fauquette et al, 2005). Two
putative AP-2-binding sites located at  316 and  244 of CDKN1B
promoter were mutated separately using the QuickChange Site-
directed mutagenesis kit (Stratagene, Agilent Technologies, Massy,
France) as previously described (Fauquette et al, 2005). The  316
site was mutated from 50-CCGCGGGC-30 to 50-TAGCGAAT-30 and
the  244 site from 50-GCCCTCCCG-30 to 50-AATCTCTAA-30. The
mutated plasmid DNA was sequenced on both strands before being
used in cell transfection experiments.
ChIP assay
The Chromatin Immuno Precipitation (ChIP) assay was carried
out as previously described (Fauquette et al, 2007) using 6mgo fa n
anti-AP-2a antibody (C18 from Santa Cruz Biotechnology) or a
normal rabbit IgG (Upstate, Millipore, St Quentin en Yvelines,
France). For the PCR, two pairs of primers were designed to
selectively amplify a distal ( 610/ 479) or a proximal region
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s( 426/ 20) of the CDKN1B promoter. PCR was carried out in a
50ml volume containing 50ng of DNA, 5U of AmpliTaq Gold
(Applied Biosystems, Courtaboeuf, France), 0.5mM of each primer,
2.5mM MgCl2 and 5% dimethylsulphoxide using the following
protocol: 3min at 951C followed by ((951C) 15s, (X111C per cycle)
15s, (721C) 15s) 10, ((951C) 15s, (X21C) 15s, (721C) 15s) 32
and 721C for 5min, where X1 and X2 were (581C, 481C) for the
distal region and (641C, 551C) for the proximal region, respec-
tively. PCR products were analysed on a 0.8% agarose gel.
Effects of gemcitabine in vitro
Gemcitabine was a kind gift from Eli Lilly (Indianapolis, IN, USA).
Cells were plated in 6-well sterile plates at a 10
5 cells per well and
were allowed to attach overnight. Cells were treated either with
0.001—100mgml
–1 of gemcitabine for 1h as previously described
(Giovannetti et al, 2004). After drug treatments were completed,
the cytotoxicity was expressed as the percentage of surviving cells
relative to untreated cultures. C5 mock cells were used as control
cell. Two independent experiments in triplicate were carried out.
Flow cytometry
Cells were treated with low doses of gemcitabine (0, 0.1 or 1mgml
–1)
during 24h before being harvested by trypsinisation, and then
resuspended in PBS. The cells were fixed by addition of 1ml of
70% ethanol and incubation on ice for 30min. Cells were then
washed with PBS, treated for 5min by RNAse A (100mgml
–1) and
finally stained with propidium iodide (50mgml
–1) for 30min. Cell
analysis was carried out on a Beckman Coulter EPICS XL3-MCL
(Villepinte, France) using the Wincycle software (Phoenix Flow
Systems, San Diego, CA, USA).
Migration assay
Cell migration properties of the different clones were assessed
using 24-well Boyden chambers (BD Bio Coat Insert 8 pm) with
8.0mm pores (BD Biosciences, Le Pont de Claix, France) following
the manufacturer protocol. Briefly, 15% foetal bovine serum was
used as chemoattractant in the lower chamber. A total of 5 10
4
cells were plated in the top chamber and were incubated for 48h.
After staining with Diffquick (Me ´diane Diagnostics, Plaisir,
France), cells on the lower surface were counted on microscopy
at  100 magnification. Eight random vision fields were counted
and the experiment was repeated four times.
Statistical analysis
Data are presented as mean±s.d. Differences in the mean of two
samples were analysed using Student’s t-test with differences
o0.05 considered significant.
RESULTS
Expression and localisation of MUC1 and MUC4 in
CAPAN-1 clones overexpressing AP-2a
We previously produced stable clones deriving from CAPAN-1 cell
line that overexpressed moderate (clones a42 and a45, one arrow
on Figure 1A) or high levels (a27 and a38, two arrows on
Figure 1A) of AP-2a, and consequently exhibited a partial to
complete inhibition of MUC4 expression, respectively (Fauquette
et al, 2007). To further characterise the pattern of expression of
these clones, levels of expression of ErbB-2 (the putative MUC4
receptor) and of the membrane-bound mucin MUC1 were
determined by western blotting. As previously shown with MUC4
Ca1 C5 27 38 42 45
ErbB-2
Parental
CAPAN1
MUC4
Apical XY section Transversal XZ section
MUC1
Apical XY section Transversal XZ section
C5 control
cells
α42 clone
α45 clone
R
MUC1
R 1 n.c. n.c. 0.25 0.36
-actin
0.61 0.73 0.66 0.31 1
Figure 1 Expression pattern of MUC1 membrane-bound mucin and ErbB-2 receptor in the CAPAN-1 clones stably transfected with an AP-2a
expression vector (a27 to a45). (A) Western blot analysis of the expression of ErbB-2 and MUC1. One or two upper arrow(s) correspond to a low or high
levels of expression of AP-2a, respectively. Bands were quantified by densitometry and a ratio (specific protein to b-actin) was calculated to evaluate
differences between mock cells and the clones. Ratio values are indicated under each panel. Total cellular extracts were used. Ca1, parental cell line; C5,
mock cells. (B) Topography of MUC1 and MUC4 expression was analysed by confocal microscopy.
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s(Fauquette et al, 2007), AP-2a overexpression is accompanied by a
decrease of the expression levels of total ErbB-2 and MUC1
(Figure 1A). A nearly complete extinction of MUC1 was observed
in clones expressing high levels of AP-2a. We further examined
whether AP-2a overexpression could affect the localisation of
MUC4 and MUC1 using confocal microscopy analysis. In parental
CAPAN-1 cells and in C5 control cells (mock cells), MUC4 was
mostly localised at the apical surface, whereas MUC1 showed both
apical and basolateral staining (Figure 1B). In a42 and a45 clones
that still expressed membrane-bound mucins, MUC4 apical
staining was strongly decreased, whereas MUC1 showed a slight
decrease of the apical staining together with an enhancement of the
basolateral staining.
Xenografts of CAPAN-1 cellular clones overexpressing
AP-2a in nude mice
Three stable clones derived from CAPAN-1 cell line were s.c.
implanted in nude mice (n¼6 mice per group): a27 and a42 clones
that stably overexpressed high and moderate levels of AP-2a
transcription factor, respectively, and the control C5 clone. As
shown in Figure 2A, the tumour volume was significantly lower in
animals xenografted with the a27 or a42 clones than in those with
the C5 clone. At day 22, the mean volume was 1766±433mm
3 in
controls (n¼6), 1014±280mm
3 in a27 (n¼6; Po0.01 vs control
clone) and 493±189mm
3 in a42 animals (n¼6; Po0.001 vs
control clone, Po0.01 vs a27). On day 28, the difference of growth
was significant only between controls (n¼3) and a42 animals
(n¼3; Po0.001).
Analysis of the expression of cell cycle regulators in
CAPAN-1-deriving clones
As a27 and a42 clones differed in terms of in vivo cell growth, we
decided to compare their transcriptome using oligoGEArrays
focused on cell cycle regulators. Results are shown in Table 1. The
a27 clone exhibited a pattern of expression suggesting an
inhibition of the cell cycle progression from the G1 to S phase
(decrease of cyclin-D1 and cdk-6 mRNAs) and from the G2 to M
phase (decrease of cyclin-G1 cyclin-A1 and cdk-5 protein partner
mRNAs). Interestingly, the a42 clone exhibited a quite different
pattern of expression characterised by an increase of CDKN1B
(p27
kip1) and CDKN1C (p57
kip2) mRNAs together with a down-
regulation of cyclin-D1 mRNA, suggesting a strong cell cycle arrest
at the G1/S phase in these cells. We try to validate our microarray
data by carrying out western blot analysis for several proteins. We
thus confirmed a decrease of CDK-4, CDK-6, cyclin-G1 and p57
kip2
in a27 clone and an increase of p57
kip2 in a42 clone. Previously we
showed that p21
cip1 and p27
kip1 protein levels were increased in
a42 clone (Fauquette et al, 2007). However, we were unable to
confirm a decrease of cyclin-D1 at the protein level in both clones.
AP-2a activates p27
kip1 promoter
We previously showed that AP-2a overexpression led to an
upregulation of p27
kip1 protein levels in pancreatic cancer cells
(Fauquette et al, 2007). As p27
kip1 expression is regulated at
transcriptional and post-transcriptional levels, we next wanted to
determine whether AP-2a could act at the promoter level. To do so,
CAPAN-1 cells were transiently cotransfected with a series of three
deletion mutants of CDKN1B promoter (Figure 3A) along with an
AP-2a expression vector. As shown in Figure 3B, loss of the  3568
to  774 nucleotides in the CDKN1B promoter did not affect AP-2a
effect that remained weak. Further deletion up to  549 nucleotides
allowed AP-2a to increase the luciferase activity of the CDKN1B
promoter activity by 4.3-fold, suggesting the presence of inhibitory
cis elements in the upstream region. Interestingly the  549/ 1
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Figure 2 Effect of AP-2a over expression on tumour growth and cell cycle. (A) In vivo tumour growth of mock CAPAN-1 cells (C5 control clone), and of
two clones overexpressing AP-2a s.c. xenografted in athymic female nude mice (n¼6 per group). Tumours were measured every 3–6 days and tumour
volume was calculated (see Materials and Methods section for further details). Data are shown as mean (points)±s.d. (error bars). *, Po0.05; **, Po0.01;
#, Po0.001. (B) Expression levels of regulators of the cell cycle were evaluated by western blotting in control C5, a42 and a27 clones. Bands were
quantified by densitometry and a ratio (specific protein to b-actin) was calculated to evaluate differences between mock cells and the clones. Ratio values are
indicated under each panel.
Table 1 Selected genes relative to the cell cycle control whose
expression was modified by AP-2a overexpression in CAPAN-1 cell line
in comparison with the control cells
Symbol Gene name
a27 clone/
C5 clone
a42 clone/
C5 clone
CCNA1 Cyclin-A1 0.31 1.57
CCND1 Cyclin-D1 0.05 0.14
CCNG1 Cyclin-G1 0.39 1.36
CDK4 Cyclin-dependant kinase 4 0.95 1.15
CDK6 Cyclin-dependant kinase 6 0.49 3.70
CDK5R1 0.07 2.11
CDK5RAP3 0.14 3.26
CDKN1A p21
cip1 0.32 0.41
CDKN1B p27
kip1 0.88 1.67
CDKN1C p57
kip2 0.05 2.28
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sregion contains two putative binding sites for AP-2 located at  315
and  243, and we decided to check their implication in AP-2a
effect by site-directed mutagenesis. Disruption of AP-2 site#1
located at  315 led to a strong reduction of AP-2a stimulatory
effect (Po0.05), whereas disruption of AP-2 site #2 at  243 had no
consequence. To decipher what happens in vivo, ChIP assay was
carried out on two regions of CDKN1B promoter, that is, a distal
part ( 610/ 479) that did not contain the two AP-2 cis elements
mentioned earlier and a proximal part ( 426/ 20) that did
contain these elements. As expected, a strong binding of AP-2a to
the proximal part of CDKN1B promoter was observed in the a45
clone that overexpressed the p27 protein (Figure 3C).
Effect of AP-2a overexpression on gemcitabine sensitivity
of pancreatic cancer cells
As the expression level of AP-2a was shown to determine the
sensitivity of colon or breast cancer cell to chemotherapeutic
drugs (Wajapeyee et al, 2005), we decided to evaluate whether
AP-2a overexpression could affect the chemosensitivity of
CAPAN-1 cells. A dose-dependent inhibition of cell proliferation
was observed with gemcitabine for all the clones tested (Figure 4A).
However, only the two clones that overexpressed moderate levels of
AP-2a (a42 and a45) exhibited a higher sensitivity to low concen-
trations of gemcitabine than the C5 control clone (Po0.05). In
contrast, the a27 and a38 clones, expressing high levels of AP-2a and
no MUC4, did not differ from control clone in terms of sensitivity to
gemcitabine. Next, the effects of low doses of gemcitabine were
further examined using flow cytometry. In absence of gemcitabine,
the cell cycle profile of C5 control cells resembled that of a27 or a42
clones with 41.6±2.3, 48.4±1.4 and 43.4±2.7% in the S phase,
respectively (not shown). In contrast, after a 24-h treatment with
0.1mgml
–1of gemcitabine, a strong cell cycle arrest in the G2 phase
was observed in the a42 clone by comparison with C5 control clone
(Po0.05). A trend toward a cell cycle arrest in G1 occurred in a27
clone but remained nonsignificant (Figure 4B). Higher doses of
gemcitabine (1mgml
–1) led to a G1 phase synchronisation for all
clones (not shown).
–3568
–774
ChIP distal region
–549
–3568
–774
–549
–549 mt#1
–549 mt#2
0123
Relative luciferase activity
AP-2 IgG INP AP-2 IgG INP
C5 45
∗
45
ChIP proximal region
Sp1 Sp1 CAAT AP-2 Sp1 AP-2
mt #1
mt #2
p27kip1
p27kip1
p27kip1
Figure 3 AP-2a activates CDKN1B by direct interactions with its promoter. (A) Schematic representation of human CDKN1B promoter. The main cis
elements for Sp1, CAAT box-binding factor and AP-2 are shown. The location of the AP-2 cis elements that undergo site-directed mutagenesis is also
shown. (B) The different CDKN1B promoter constructs were transiently cotransfected with 0.2mg of pRSV-AP-2a or corresponding empty vector. Results
are expressed as fold induction of luciferase activity relative to the empty expression vector (value was set at 1.0). Values are means±s.d. for two
independent experiments in which cotransfections were run in triplicate (*, Po0.05). (C) ChIP assay. AP-2 represents the fraction precipitated with the anti-
AP-2a antibody, IgG those precipitated with a normal rabbit IgG. PCR results obtained on the proximal region are shown.
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sMigration assay
Previous studies conducted in our laboratory showed that stably
overexpressed AP-2a cells displayed a significant decrease of their
invasion capacity in vitro (Fauquette et al, 2007). In this study, cell
migration was evaluated using Boyden chambers. As shown in
Figure 5, the number of migrating cells strongly decreases in all
overexpressing AP-2a cells clones compared with the C5 control
clone (Po0.05 for a27 and Po0.001 for a38, a42 and a45 vs
control C5), suggesting that AP-2a has a major role in migration
properties of pancreatic cancer cells in vitro. Interestingly, a42
cells migrated less than a27 cells in vitro (Po0.05) in accordance
with their different behaviour in vivo (Figure 2A).
DISCUSSION
In a previous study we showed that AP-2a expression concerned
only 5.5% of human PDAC tissues, whereas it was expressed by
nontumoural pancreatic ductal cells (Fauquette et al, 2007). We
therefore hypothesised whether such a loss of expression of AP-2a,
which is considered as a TSG in different tissues (Ruiz et al, 2001;
Schwartz et al, 2007), could contribute to pancreatic carcino-
genesis. To address this question, we took advantage of stable
clones deriving from CAPAN-1 cells and overexpressing AP-2a
that we previously generated (Fauquette et al, 2007).
In this study, we found that a moderate overexpression of AP-2a
significantly inhibits pancreatic tumour growth in animal models.
Our experimental data, together with recent results obtained on
different cell lines (Orso et al, 2008), suggested that this anti-
tumour activity resulted from a cell cycle arrest as we previously
showed that the cyclin-dependent kinase inhibitor p27
kip1 protein
levels in pancreatic cancer cells were strongly increased after
an AP-2a overexpression (Fauquette et al, 2007). Moreover, the
growth curves of the tumours deriving from the xenografted clones
are inversely correlated to the p27
kip1 protein levels. We therefore
decided to evaluate whether AP-2a could regulate p27
kip1
expression. Here we further showed that AP-2a could induce
CDKN1B promoter activity directly by interacting with two
proximal AP-2 cis elements located at  316 and  244. Interest-
ingly, the same proximal region of CDKN1B promoter was recently
shown to contain three cis elements for KLF4 transcription factor
close to the AP-2 sites and to be induded by KLF4 in pancreatic
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Figure 4 Effect of AP-2a over expression on gemcitabine sensitivity of pancreatic cancer cells. (A) In vitro growth-inhibitory effect of gemcitabine against
the mock CAPAN-1 cells (C5) and the four clones that stably overexpressed AP-2a transcription factor. Cell growth was assessed by cell counting of
surviving cells. For each cell line, results are expressed as the percentage of surviving cells relative to the untreated cells that were arbitrarily given a 100%
value. Results are shown as mean of two independent experiments run in triplicate. *, Po0.05. (B) Cell cycle distribution profiles of C5 control cells, a27 and
a42 treated with 0.1mgml
–1 of gemcitabine for 24h. The values are expressed as the mean of three independent experiments.
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Figure 5 Migration assay. Migration properties of mock CAPAN-1 cells
(C5 control clone) and clones overexpressing AP-2a (a27, a38, a42 and
a45) were evaluated using Boyden chambers. Results are expressed as
average migratory cell number per vision field (mean±s.e.m., *, Po0.05,
#, Po0.001).
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scancer cell lines (Wei et al, 2008). Moreover, KLF4 overexpression
led to a suppression of tumour cell growth both in vitro and
in vivo, as shown for AP-2a. Whether AP-2a and KLF4 could
cooperate on CDKN1B proximal promoter remains to be defined.
We next try to further document the impact of AP-2a on the cell
cycle regulators. Microarray analysis and western blotting allowed
us to distinguish changes in gene expression linked to AP-2a
overexpression that were independent (observed in a27 clone) or
dependent of MUC4 expression (only seen in a42 clone). In
absence of membrane-bound mucins, AP-2a represses the expres-
sion of the CDK-4 and CDK-6 that are activated during the G1
phase of the cell cycle (Malumbres and Barbacid, 2009) in presence
of their protein partner (cyclin D). These variations are expected to
promote a G1 phase arrest in a27 clone. Decrease of CDK-4 seems
of special interest as its constitutive activation in a mice model
results in epithelial tumours affecting the gut, liver and digestive
exocrine glands (Sotillo et al, 2001). CDK-4 thus has a central role
in epithelial proliferation control. In contrast, MUC4 expression
reverses the AP-2a-induced CDK-4 decrease but, in the same time,
is associated with an upregulation of the CDK-I p27
kip1, p57
kip2
and p21
cip1 (Fauquette et al, 2007). We therefore speculate that
MUC4 could trigger the G1 phase arrest initiated by AP-2a
overexpression. This result was expected in light of previous data
showing that the rat Muc4 interacts with ErbB-2 receptor, that is
expressed in a42 clone, and induces p27
kip1 expression (Jepson
et al, 2002).
We also showed that a moderate overexpression of AP-2a in
CAPAN-1 cells resulted in an increase of the chemosensitivity to
low doses of gemcitabine. This original result, potentially relevant
for pancreatic cancer therapy in which gemcitabine is the first-line
treatment, was however expected as AP-2a was previously shown
to increase colon cancer cell sensitivity to chemotherapy. This
effect was independent of p53 (Wajapeyee et al, 2005) and resulted
from a downregulation of Bcl-2 and an induction of apoptosis
(Wajapeyee et al, 2006). Moreover, the same group also showed
that AP-2 was induced by a post-transcriptional mechanism by
various chemotherapeutic agents such as adriamycin or cisplatin.
However, no data are currently available in the literature to
support such an effect for gemcitabine.
Another question to address is whether the decrease of MUC1
and MUC4 expression could contribute to the AP-2a-induced
sensitisation of pancreatic cancer cells to gemcitabine. Indeed,
recent studies showed that MUC1 overexpression in carcinoma
cells increases their refractoriness to chemotherapeutic drug-
induced apoptosis (Ren et al, 2004; Kalra and Campbell, 2007).
Accordingly, knockdown of MUC1 sensitises thyroid cancer cells
to doxorubicine through activation of the intrinsic apoptotic
pathway (Siragusa et al, 2007). Concerning MUC4, its silencing by
shRNA in the pancreatic CD18-HPAF cell line led to a significant
increase of apoptosis and to an induction of apoptosis mediators,
such as caspase-2, caspase-3 and caspase-7, and a repression of the
anti-apoptotic protein S100A4 (Chaturverdi et al, 2007). However,
there is no report in the literature showing that MUC4 silencing
could enhance the cytotoxic action of chemotherapeutic drugs
such as gemcitabine. Therefore, we speculate that in our cellular
model, a slight decrease of MUC4 expression could potentiate AP-
2a pro-apoptotic effect. On the opposite, a complete extinction of
MUC4 expression seems unfavourable in terms of sensitivity to
gemcitabine.
In conclusion, our results suggested that AP-2a overexpression
could be exploited to decrease the in vivo tumour growth of
pancreatic cancer cells and probably to increase their sensitivity to
conventional chemotherapy.
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